KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Consolidated Net Income (2016 - 2026)

Emergent BioSolutions has reported Consolidated Net Income over the past 15 years, most recently at $6.8 million for Q1 2026.

  • For Q1 2026, Consolidated Net Income fell 90.0% year-over-year to $6.8 million; the TTM value through Mar 2026 reached -$8.6 million, up 93.47%, while the annual FY2025 figure was $52.6 million, 127.6% up from the prior year.
  • Consolidated Net Income for Q1 2026 was $6.8 million at Emergent BioSolutions, up from -$54.6 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $114.8 million in Q3 2024 and troughed at -$283.1 million in Q2 2024.
  • A 5-year average of -$65.1 million and a median of -$49.5 million in 2023 define the central range for Consolidated Net Income.
  • Biggest five-year swings in Consolidated Net Income: tumbled 4932.43% in 2023 and later skyrocketed 655.56% in 2025.
  • Year by year, Consolidated Net Income stood at -$67.0 million in 2022, then rose by 26.12% to -$49.5 million in 2023, then soared by 36.77% to -$31.3 million in 2024, then crashed by 74.44% to -$54.6 million in 2025, then surged by 112.45% to $6.8 million in 2026.
  • Business Quant data shows Consolidated Net Income for EBS at $6.8 million in Q1 2026, -$54.6 million in Q4 2025, and $51.2 million in Q3 2025.